Leon Kircik

6PUBLICATIONS
44CO-AUTHORS
Epidemiological methodsPharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)Allergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 21, 2026
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

|Jul 22, 2025
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.

Andrew F Alexis, Leon Kircik, Raj Chovatiya

|Mar 21, 2025
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.

April W Armstrong, Leon Kircik, Linda Stein Gold

|Jul 12, 2024
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.

Eric L Simpson, Leon Kircik, Andrew Blauvelt

|Dec 20, 2023
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis.

Leon Kircik, Matthew Zirwas, Shawn G Kwatra

|Oct 01, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

A Wollenberg, A Blauvelt, E Guttman-Yassky

Pageof 1

Frequent Collaborators

2 joint publications

Andrew Blauvelt

2 joint publications

April W Armstrong

2 joint publications

Pedro Herranz

2 joint publications

Anna M Tallman